한글목차

아이젠멩거 증후군 치료 동향 및 전망

세계 아이젠멩거 증후군 치료 시장은 2024년부터 2030년까지 연평균 5.8%의 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 아이젠 멩거 증후군으로 고통받는 환자 수의 증가와 첨단 약물 개발과 관련된 연구 개발 활동에 대한 관심이 증가하고 있습니다. 세계 아이젠멩거 증후군 치료 시장의 미래는 병원 약국, 온라인 약국, 소매 약국 시장에서의 기회로 인해 유망한 전망을 보이고 있습니다.

아이젠멩거 증후군 치료

이 보고서는 전 세계 아이젠멩거 증후군 치료의 약물 유형별, 유통 채널별, 지역별 예측을 담고 있습니다.

아이젠멩거 증후군 치료 시장 인사이트

Lucintel의 예측에 따르면, 엔도텔린 수용체 길항제는 다양한 합병증 관리에 광범위하게 영향을 미치고 잠재적으로 낮은 비용으로 인해 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.

이 시장 중 병원 약국이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

북미는 만성질환의 증가와 첨단 의료기술의 높은 채택률로 인해 예측 기간 동안 가장 큰 지역으로 남을 것입니다.

자주 묻는 질문

Q1. 시장 성장 예측은?

A1. 세계 아이젠멩거 증후군 치료 시장은 2024년부터 2030년까지 연평균 5.8%의 성장률을 보일 것으로 예상됩니다.

Q2. 시장 성장에 영향을 미치는 주요 촉진요인은?

A2. 이 시장의 주요 촉진요인은 아이젠멩거 증후군 환자 수의 증가와 첨단 의약품 개발과 관련된 연구 개발 활동에 대한 관심 증가입니다.

Q3. 시장의 주요 부문은?

A3. 아이젠멩거 증후군 치료 시장의 전망은 병원 약국, 온라인 약국, 소매 약국 시장에서의 기회로 인해 더욱 유망합니다.

Q4. 시장의 주요 기업은?

A4. 아이젠멩거 증후군 치료의 주요 기업은 다음과 같습니다.

• Actelion Pharmaceuticals
• Gilead Sciences
• Pfizer
• Teva Pharmaceutical Industries
• AstraZeneca
• Novartis
• Merck & Co
• GlaxoSmithKline
• Mylan
• Bayer

Q5. 향후 가장 큰 시장 부문은?

A5. Lucintel은 엔도텔린 수용체 길항제가 다양한 합병증 관리에 광범위하게 영향을 미치고 잠재적으로 저렴한 비용으로 인해 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상했습니다.

Q6. 시장에서 향후 5년간 가장 큰 시장이 될 것으로 예상되는 지역은?

A6. 북미는 만성질환의 증가와 첨단 의료기술의 높은 채택률로 인해 예측 기간 동안 가장 큰 지역으로 남을 것으로 예상됩니다.

Q7. 보고서 사용자 정의가 가능합니까?

A7. 예, Lucintel은 추가 비용없이 10%의 사용자 정의를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 아이젠멩거 증후군 치료 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2018년부터 2030년까지 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 아이젠멩거 증후군 치료 시장 동향(2018-2023년)과 예측(2024-2030년)
• 약물 유형별 아이젠멩거 증후군 치료 세계 시장
  • 항부정맥제
  • 혈액응고 저지약
  • 엔도텔린 수용체 길항제
  • 기타
• 유통 채널별 아이젠멩거 증후군 치료 세계 시장
  • 병원 약국
  • 온라인 약국
  • 소매 약국

제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석

• 지역별 아이젠멩거 증후군 치료 시장
• 북미의 아이젠멩거 증후군 치료 시장
• 유럽의 아이젠멩거 증후군 치료 시장
• 아시아태평양의 아이젠멩거 증후군 치료 시장
• 기타 지역의 아이젠멩거 증후군 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 업무 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
• 세계의 아이젠멩거 증후군 치료 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 아이젠멩거 증후군 치료 시장 능력 확대
  • 세계의 아이젠멩거 증후군 치료 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Actelion Pharmaceuticals
• Gilead Sciences
• Pfizer
• Teva Pharmaceutical Industries
• AstraZeneca
• Novartis
• Merck & Co
• GlaxoSmithKline
• Mylan
• Bayer

영문목차

Eisenmenger Syndrome Treatment Trends and Forecast

The future of the global eisenmenger syndrome treatment market looks promising with opportunities in the hospital pharmacies, online pharmacies, and retail pharmacies markets. The global eisenmenger syndrome treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are growing number of patients suffering from eisenmenger syndrome and rising focus on r&d activities related to the development of advanced drugs.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Eisenmenger Syndrome Treatment by Segment

The study includes a forecast for the global eisenmenger syndrome treatment by drug type, distribution channel, and region.

Eisenmenger Syndrome Treatment Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Antiarrhythmic Agents
• Blood Thinning Agents
• Endothelin Receptor Antagonist
• Others

Eisenmenger Syndrome Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Eisenmenger Syndrome Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Eisenmenger Syndrome Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies eisenmenger syndrome treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the eisenmenger syndrome treatment companies profiled in this report include-

• Actelion Pharmaceuticals
• Gilead Sciences
• Pfizer
• Teva Pharmaceutical Industries
• AstraZeneca
• Novartis
• Merck & Co
• GlaxoSmithKline
• Mylan
• Bayer

Eisenmenger Syndrome Treatment Market Insights

Lucintel forecasts that endothelin receptor antagonist is expected to witness the highest growth over the forecast period due to their broader impact on managing various complications and potentially lower cost.

Within this market, hospital pharmacies is expected to witness the highest growth over the forecast period.

North America will remain the largest region over the forecast period due to increasing incidences of chronic diseases and higher adoption rate of advanced medical technologies in the region.

Features of the Global Eisenmenger Syndrome Treatment Market

Market Size Estimates: Eisenmenger syndrome treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Eisenmenger syndrome treatment market size by drug type, distribution channel, and region in terms of value ($B).

Regional Analysis: Eisenmenger syndrome treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, distribution channels, and regions for the eisenmenger syndrome treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the eisenmenger syndrome treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for eisenmenger syndrome treatment market?

Answer: The global eisenmenger syndrome treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the eisenmenger syndrome treatment market?

Answer: The major drivers for this market are growing number of patients suffering from eisenmenger syndrome and rising focus on r&d activities related to the development of advanced drugs.

Q3. What are the major segments for eisenmenger syndrome treatment market?

Answer: The future of the eisenmenger syndrome treatment market looks promising with opportunities in the hospital pharmacies, online pharmacies, and retail pharmacies markets.

Q4. Who are the key eisenmenger syndrome treatment market companies?

Answer: Some of the key eisenmenger syndrome treatment companies are as follows:

• Actelion Pharmaceuticals
• Gilead Sciences
• Pfizer
• Teva Pharmaceutical Industries
• AstraZeneca
• Novartis
• Merck & Co
• GlaxoSmithKline
• Mylan
• Bayer

Q5. Which eisenmenger syndrome treatment market segment will be the largest in future?

Answer: Lucintel forecasts that endothelin receptor antagonist is expected to witness the highest growth over the forecast period due to their broader impact on managing various complications and potentially lower cost.

Q6. In eisenmenger syndrome treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing incidences of chronic diseases and higher adoption rate of advanced medical technologies in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the eisenmenger syndrome treatment market by drug type (antiarrhythmic agents, blood thinning agents, endothelin receptor antagonist, and others), distribution channel (hospital pharmacies, online pharmacies, and retail pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Eisenmenger Syndrome Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Eisenmenger Syndrome Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Eisenmenger Syndrome Treatment Market by Drug Type
  • 3.3.1: Antiarrhythmic Agents
  • 3.3.2: Blood Thinning Agents
  • 3.3.3: Endothelin Receptor Antagonist
  • 3.3.4: Others
• 3.4: Global Eisenmenger Syndrome Treatment Market by Distribution Channel
  • 3.4.1: Hospital Pharmacies
  • 3.4.2: Online Pharmacies
  • 3.4.3: Retail Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Eisenmenger Syndrome Treatment Market by Region
• 4.2: North American Eisenmenger Syndrome Treatment Market
  • 4.2.1: North American Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
  • 4.2.2: North American Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.3: European Eisenmenger Syndrome Treatment Market
  • 4.3.1: European Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
  • 4.3.2: European Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.4: APAC Eisenmenger Syndrome Treatment Market
  • 4.4.1: APAC Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
  • 4.4.2: APAC Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.5: ROW Eisenmenger Syndrome Treatment Market
  • 4.5.1: ROW Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
  • 4.5.2: ROW Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Region
• 6.2: Emerging Trends in the Global Eisenmenger Syndrome Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Eisenmenger Syndrome Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Eisenmenger Syndrome Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Actelion Pharmaceuticals
• 7.2: Gilead Sciences
• 7.3: Pfizer
• 7.4: Teva Pharmaceutical Industries
• 7.5: AstraZeneca
• 7.6: Novartis
• 7.7: Merck & Co
• 7.8: GlaxoSmithKline
• 7.9: Mylan
• 7.10: Bayer